Table 3 The global top ten sales of drug in the first half of 2018
From: Cell death-related molecules and biomarkers for renal cell carcinoma targeted therapy
No. | Drugs | Target | Category | Indications |
|---|---|---|---|---|
1 | Adalimumab | TNF | McAb | Autoimmune disease (rheumatoid arthritis; ankylosing spondylitis) |
2 | Apixaban | Factor Xa | Chemical drugs | For the prevention of venous thromboembolic events (VTE) in adults undergoing elective hip or knee replacement |
3 | Lenalidomide | Non-specific (immune regulation and anti-angiogenesis) | Chemical drugs | Multiple myeloma |
4 | Trastuzumab | HER2 | McAb | Metastatic breast cancer and gastric cancer; adjuvant therapy of breast cancer |
5 | Rituximab | CD20 | McAb | Therapy or combined therapy for specific type of non-hodgkin’s lymphoma |
6 | Etanercept | TNF | Fusion protein | Autoimmune disease (rheumatoid arthritis; ankylosing spondylitis) |
7 | Bevacizumab | VEGF | McAb | Combined therapy with chemotherapeutics for metastatic colorectal cancer and non-resectable advanced metastatic or recurrent non-squamous cell non-small cell lung cancer |
8 | Nivolumab | PD-1 | McAb | Various specific type of advanced or metastatic cancers (melanoma; non-small cell lung cancer; renal cell carcinoma; head and neck squamous carcinoma; metastatic colorectal cancer; urothelial carcinoma; hepatoma) treated with corresponding anti-tumor drugs or containing corresponding biomarker |
9 | Pembrolizumab | PD-1 | McAb | The treatment of an unresectable or metastatic melanoma that fails in first-line treatment |
10 | Infliximab | TNF | McAb | Autoimmune disease (active ankylosing spondylitis; ulcerative colitis, moderate or severe Crohn’s disease and fistula Crohn’s disease with poor conventional treatment; moderate or severe chronic plaque psoriasis and joint psoriasis; combined with methotrexate to treat moderate or severe active rheumatoid arthritis) |